links for 2009-08-06
-
In patients with advanced non-small-cell lung cancer (NSCLC), the addition of the targeted agent cetuximab (Erbitux) to platinum-based chemotherapy offers a small survival advantage. Patients given chemotherapy plus cetuximab had a median overall survival of 11.3 months, compared with 10.1 months for control subjects. Is a month enough given the high cost of the therapy? Should we expect more?
-
Vandetanib Has Some Advantage Over Gefitinib in Non-Small-Cell Lung Canc…Vandetanib demonstrated a significant prolongation of progression-free survival compared with gefitinib in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) in a recent study by U.S. and European researchers. However, overall survival was not improved.
-
New results from the phase 3 SATURN trial show that erlotinib (Tarceva) maintenance therapy significantly improves overall survival in nonsmall-cell lung cancer (NSCLC) patients. However, although the survival was significant, the real improvement was only one extra month of benefit.
-
Achieving an early response with imatinib is protective against treatment failure; second-generation tyrosine kinase inhibitors (TKIs; for example, nilotinib, dasatinib, bosutinib), however, have proven to be efficacious at restoring cytogenetic responses in patients who require subsequent therapy. Response duration, however, is yet to be established and a considerable proportion of patients fail to achieve a clinically meaningful response.
-
In imatinib-treated CML, secondary drug resistance is often caused by mutations in the BCR-ABL kinase domain (KD). As alternative therapies are available for imatinib resistance, early identification of mutations may prevent disease progression. Since most patients are routinely monitored by BCR-ABL quantitative PCR, it is important to define the optimal increase in BCR-ABL that should trigger mutation testing. Patients with CML who have a 2.6-fold or greater increase in BCR-ABL RNA transcript levels by RQ-PCR should be screened for kinase-domain mutations associated with imatinib resistance.